Clinical trial
A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, and Exposure of up to 12 Weeks of XPF-005 Treatment in Healthy Volunteers and Subjects With Acne Vulgaris
NCT02656043 is registered in ClinicalTrials.gov with Xenon Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, and Exposure of up to 12 Weeks of XPF-005 Treatment in Healthy Volunteers and Subjects With Acne Vulgaris
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- September 17, 2015
- Completion date
- March 17, 2017
- Enrollment
- 213 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.